# Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)

> **NCT05177926** · PHASE4 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 330 (estimated)

## Conditions studied

- Hepatitis B, Chronic
- Mother to Child Transmission

## Interventions

- **DRUG:** antiviral prophylaxis with Tenofovir Alafenamide Fumarate

## Key facts

- **NCT ID:** NCT05177926
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-04
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2022-01-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177926, "Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05177926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*